Ionis drug ulefnersen meets primary endpoint in FUS-ALS Phase 3 trial

September 22, 2026 8:01 AM

Ionis Pharmaceuticals (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization announced positive topline results from the Phase 3 FUSION trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found